SCHEMBL4483280

SCHEMBL4483280

Cc1ccc(S(=O)(=O)Oc2cccc3c(S(=O)(=O)NCc4cccc(N)c4)cccc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.50
MEN1 O00255 1/20 0.49
ESR1 P03372 1/20 0.49
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49
ESR2 Q92731 1/20 0.49
NSD2 O96028 8/20 0.46
FABP4 P15090 1/20 0.45
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 1/20 0.43
CA12 O43570 1/20 0.43
ATM Q13315 1/20 0.43
CA9 Q16790 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NOS2 P35228 2/20 0.42
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
NPY5R Q15761 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482026 0.88 CA12 (0.56) CYP19A1MEN1ESR1GAAKMT2A
SCHEMBL4479415 0.87 L3MBTL1 (0.52) CYP19A1MEN1ESR1GAAKMT2A
SCHEMBL4483089 0.85 CYP2C19 (0.65) CYP19A1MEN1ESR1GAAKMT2A
SCHEMBL4487088 0.85 MEN1 (0.57) CYP19A1MEN1ESR1GAAKMT2A
SCHEMBL4483934 0.84 MEN1 (0.52) CYP19A1MEN1ESR1GAAKMT2A
SCHEMBL4489698 0.84 NSD2 (0.49) CYP19A1MEN1ESR1GAAKMT2A
SCHEMBL4473385 0.82 MEN1 (0.50) CYP19A1MEN1ESR1GAAKMT2A
SCHEMBL4472800 0.82 POLB (0.57) MEN1GAAKMT2AATML3MBTL1
SCHEMBL4477941 0.82 MEN1 (0.49) CYP19A1MEN1ESR1GAAKMT2A
SCHEMBL4483773 0.81 MEN1 (0.60) CYP19A1MEN1ESR1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 CYP19A1 552/4885MEN1 4507/4885ESR1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.